Company Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States.
Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.
The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19.
It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300.
The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015.
Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 73 |
| CEO | Michael J. McElhaugh |
Contact Details
Address: 701 Veterans Circle Warminster, Pennsylvania 18974 United States | |
| Phone | 604-419-3200 |
| Website | arbutusbio.com |
Stock Details
| Ticker Symbol | ABUS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001447028 |
| CUSIP Number | 03879J100 |
| ISIN Number | CA03879J1003 |
| Employer ID | 98-0597776 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael J. McElhaugh | Co-Founder, Interim President, Chief Executive Officer and Director |
| Dr. Michael J. Sofia Ph.D. | Chief Scientific Officer |
| David C. Hastings CPA | Chief Financial Officer and Chief Accounting Officer |
| Lisa M. Caperelli | Vice President of Investor Relations |
| J. Christopher Naftzger BA, Esq., J.D. | General Counsel, Chief Compliance Officer and Secretary |
| Shannon Briscoe SPHR | Vice President of Human Resources |
| Dr. Karen Sims M.D., Ph.D. | Chief Medical Officer |
| R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C. | Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 10, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 10, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 4, 2024 | 8-K | Current Report |
| Mar 5, 2024 | 10-K | Annual Report |
| Feb 29, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 8, 2024 | 8-K | Current Report |
| Jan 4, 2024 | 8-K | Current Report |